Don Siegel

Dr. Siegel is a Professor of Pathology & Laboratory Medicine at the University of Pennsylvania’s School of Medicine. He is the Director of the Division of Transfusion Medicine & Therapeutic Pathology and of the Clinical Cell & Vaccine Production Facility, within the Center for Advanced Cellular Therapies. Dr. Siegel’s research has been supported by NIH funding in areas of immunohematology, hemostasis/thrombosis, autoimmunity, and oncology since 1992. He is an internationally recognized authority in antibody phage display and has been responsible for generating scFv phage display libraries from many different animal species. He is responsible for the manufacture of gene-modified human T cell therapies at UPenn for numerous clinical trials including the first genetically modified cellular therapy approved by FDA and licensed by UPenn to Novartis (tisagenlecleucel, Kymriah™).